Sionna Therapeutics — Third Quarter 2026 Earnings Summary

Sionna Therapeutics announced plans to advance its SION-451 and SION-2222 dual combination into the AscenSION CF Phase 2 proof-of-concept trial, expected to begin in the first quarter of 2027. The company reported a net loss of $32.4 million for the third quarter of 2026, driven by increased research and development expenses and restructuring costs associated with a 46% workforce reduction. As of September 30, 2026, Sionna held $249.8 million in cash and cash equivalents, which is projected to fund operations through the second half of 2029. Clinical and nonclinical data presented at the 2026 North American Cystic Fibrosis Conference support the potential of NBD1 stabilizer combinations to benefit a broad population of people with cystic fibrosis.